1. Home
  2. ACAD vs SFBS Comparison

ACAD vs SFBS Comparison

Compare ACAD & SFBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$21.84

Market Cap

3.9B

Sector

Health Care

ML Signal

N/A

Logo ServisFirst Bancshares Inc.

SFBS

ServisFirst Bancshares Inc.

N/A

Current Price

$76.82

Market Cap

4.0B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ACAD
SFBS
Founded
1993
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.0B
IPO Year
2000
2014

Fundamental Metrics

Financial Performance
Metric
ACAD
SFBS
Price
$21.84
$76.82
Analyst Decision
Buy
Buy
Analyst Count
22
3
Target Price
$30.55
$87.50
AVG Volume (30 Days)
1.6M
245.8K
Earning Date
05-06-2026
04-20-2026
Dividend Yield
N/A
1.98%
EPS Growth
69.12
21.63
EPS
2.30
5.06
Revenue
$726,437,000.00
N/A
Revenue This Year
$18.80
$32.30
Revenue Next Year
$11.70
$10.30
P/E Ratio
$9.45
$15.18
Revenue Growth
40.45
N/A
52 Week Low
$14.08
$66.48
52 Week High
$28.35
$90.64

Technical Indicators

Market Signals
Indicator
ACAD
SFBS
Relative Strength Index (RSI) 49.16 50.96
Support Level $21.51 $71.32
Resistance Level $22.03 $83.76
Average True Range (ATR) 0.70 1.69
MACD 0.08 0.60
Stochastic Oscillator 57.43 59.45

Price Performance

Historical Comparison
ACAD
SFBS

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

About SFBS ServisFirst Bancshares Inc.

Servisfirst Bancshares Inc is a bank holding company whose business is conducted by its wholly owned subsidiary. Through the subsidiary, it offers various banking services to individual and corporate customers in Birmingham, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. Its various products and service offerings include commercial, consumer, and other loans; accepting deposits; providing electronic banking services, such as online and mobile banking, including remote deposit capture; delivering treasury and cash management services; and providing banking services to other financial institutions. The company operates as a single reportable segment, with a majority of its revenue being derived from the business of banking.

Share on Social Networks: